OBJECTIVES: Despite significant medical advances, infective endocarditis (IE) remains an infection associated with high morbidity and mortality. The objective was to assess the safety and efficacy of high-dose daptomycin, defined as ≥ 8 mg/kg/day, in patients with confirmed or suspected staphylococcal and/or enterococcal IE. METHODS: This was a multicentre, retrospective observational study (2005-11). Adult patients, not undergoing haemodialysis, with blood cultures positive for staphylococci or enterococci and a definitive or possible diagnosis of IE, who received daptomycin ≥ 8 mg/kg/day (based on total body weight) for ≥ 72 h were included. RESULTS: Seventy patients met the inclusion criteria and comprised 33 (47.1%) with right-sided IE (RIE), 35 (50%) with left-sided IE (LIE) and 2 with both RIE and LIE. Several patients had concomitant sites of infection, with bone/joint infection being most prevalent (12.9%). Sixty-five patients received daptomycin as salvage therapy. Pathogens were isolated from 64 patients, with methicillin-resistant Staphylococcus aureus as the most common organism (84.4%), followed by vancomycin-resistant Enterococcus faecium (7.8%). The median (IQR) daptomycin dose was 9.8 mg/kg/day (8.2-10.0 mg/kg/day), and was similar in RIE and LIE patients (9.8 and 9.3 mg/kg/day, respectively). A total of 24 (34.3%) received combination therapy. For those patients with pathogens isolated (n = 64), the organism was eradicated in 57 (89.1%) patients. Among 64 clinically evaluable patients, 55 (85.9%) achieved clinical success. No patients required discontinuation of high-dose daptomycin due to creatine phosphokinase elevations. CONCLUSIONS: Patients with both RIE and LIE had successful outcomes with high-dose daptomycin therapy. Additional clinical trials evaluating high daptomycin dosages in patients with IE are warranted.
OBJECTIVES: Despite significant medical advances, infective endocarditis (IE) remains an infection associated with high morbidity and mortality. The objective was to assess the safety and efficacy of high-dose daptomycin, defined as ≥ 8 mg/kg/day, in patients with confirmed or suspected staphylococcal and/or enterococcal IE. METHODS: This was a multicentre, retrospective observational study (2005-11). Adult patients, not undergoing haemodialysis, with blood cultures positive for staphylococci or enterococci and a definitive or possible diagnosis of IE, who received daptomycin ≥ 8 mg/kg/day (based on total body weight) for ≥ 72 h were included. RESULTS: Seventy patients met the inclusion criteria and comprised 33 (47.1%) with right-sided IE (RIE), 35 (50%) with left-sided IE (LIE) and 2 with both RIE and LIE. Several patients had concomitant sites of infection, with bone/joint infection being most prevalent (12.9%). Sixty-five patients received daptomycin as salvage therapy. Pathogens were isolated from 64 patients, with methicillin-resistant Staphylococcus aureus as the most common organism (84.4%), followed by vancomycin-resistant Enterococcus faecium (7.8%). The median (IQR) daptomycin dose was 9.8 mg/kg/day (8.2-10.0 mg/kg/day), and was similar in RIE and LIE patients (9.8 and 9.3 mg/kg/day, respectively). A total of 24 (34.3%) received combination therapy. For those patients with pathogens isolated (n = 64), the organism was eradicated in 57 (89.1%) patients. Among 64 clinically evaluable patients, 55 (85.9%) achieved clinical success. No patients required discontinuation of high-dose daptomycin due to creatine phosphokinase elevations. CONCLUSIONS:Patients with both RIE and LIE had successful outcomes with high-dose daptomycin therapy. Additional clinical trials evaluating high daptomycin dosages in patients with IE are warranted.
Authors: J S Li; D J Sexton; N Mick; R Nettles; V G Fowler; T Ryan; T Bashore; G R Corey Journal: Clin Infect Dis Date: 2000-04-03 Impact factor: 9.079
Authors: Ashley D Hall; Molly E Steed; Cesar A Arias; Barbara E Murray; Michael J Rybak Journal: Antimicrob Agents Chemother Date: 2012-04-02 Impact factor: 5.191
Authors: Vance G Fowler; Jose M Miro; Bruno Hoen; Christopher H Cabell; Elias Abrutyn; Ethan Rubinstein; G Ralph Corey; Denis Spelman; Suzanne F Bradley; Bruno Barsic; Paul A Pappas; Kevin J Anstrom; Dannah Wray; Claudio Q Fortes; Ignasi Anguera; Eugene Athan; Philip Jones; Jan T M van der Meer; Tom S J Elliott; Donald P Levine; Arnold S Bayer Journal: JAMA Date: 2005-06-22 Impact factor: 56.272
Authors: Robert D Arbeit; Dennis Maki; Francis P Tally; Edward Campanaro; Barry I Eisenstein Journal: Clin Infect Dis Date: 2004-05-20 Impact factor: 9.079
Authors: Scott K Fridkin; Rachel Lawton; Jonathan R Edwards; Fred C Tenover; John E McGowan; Robert P Gaynes Journal: Emerg Infect Dis Date: 2002-07 Impact factor: 6.883
Authors: Ashley D Hall Snyder; Brian J Werth; Poochit Nonejuie; John P McRoberts; Joe Pogliano; George Sakoulas; Juwon Yim; Nivedita Singh; Michael J Rybak Journal: Antimicrob Agents Chemother Date: 2016-09-23 Impact factor: 5.191
Authors: Antonio D'Avolio; Debora Pensi; Lorena Baietto; Giovanni Pacini; Giovanni Di Perri; Francesco Giuseppe De Rosa Journal: Drugs Date: 2016-08 Impact factor: 9.546
Authors: Thomas L Holland; Larry M Baddour; Arnold S Bayer; Bruno Hoen; Jose M Miro; Vance G Fowler Journal: Nat Rev Dis Primers Date: 2016-09-01 Impact factor: 52.329
Authors: Camille Castel; Arnaud de La Blanchardière; Jocelyn Michon; Vincent Cattoir; Guillaume Saint-Lorant Journal: Int J Clin Pharm Date: 2016-03-07
Authors: Jordan R Smith; Katie E Barber; Animesh Raut; Mostafa Aboutaleb; George Sakoulas; Michael J Rybak Journal: J Antimicrob Chemother Date: 2015-02-01 Impact factor: 5.790